5 recruiting, 3 unknown, 1 active not recruiting, 1 terminated. 6 Early Phase 1, 2 Not applicable, 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 6 | Unknown 3, Recruiting 2, Active not recruiting 1 |
| Not applicable | 2 | Recruiting 2 |
| Phase 2 | 2 | Recruiting 1, Terminated 1 |
| Phase 1 | 1 | Recruiting 1 |
Follow 68Ga-pentixafor: new trials by email Literature Review of 68Ga-pentixafor trials Research Report on 68Ga-pentixafor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Application of 68Ga-Pentixafor PET/CT for Thymoma 68Ga-Pentixafor - Thymoma | Early Phase 1 | Unknown | Peking Union Medical College Hospital | 100 | 2023-06-22 | 2023-10-17 |
| Diagnostic Value of CXCR4-targeted PET/CT in ACTH-dependent and Independent Cushing's Syndrome 68Ga-Pentixafor - Cushing s Syndrome | Phase 1 / Phase 2 | Recruiting | Peking Union Medical College Hospital | 160 | 2023-06-12 | 2026-01-20 |
| [68Ga]Ga-PentixaFor PET Imaging in CNS Lymphoma Patients 68Ga-PTF - CNS Lymphoma | Phase 2 | Terminated | Pentixapharm AG | 1 | 2022-10-05 | 2025-09-05 |
| CXCR4-targeted PET/CT Imaging in Hematological Malignancies 68Ga-pentixafor, PET/CT - CXCR4, PET/CT | Not applicable | Recruiting | Zhongnan Hospital | 300 | 2022-03-01 | 2025-06-26 |
| In-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET [68Ga]-Pentixafor - Non-Hodgkin Lymphoma, Multiple Myeloma | Early Phase 1 | Recruiting | Memorial Sloan Kettering Cancer Center | 30 | 2021-10-01 | 2026-02-05 |
| 68Ga-pentixather and 68Ga-pentixafor PET/CT in Multiple Myeloma 68Ga-Pentixather, 68Ga-Pentixafor - Multiple Myeloma | Early Phase 1 | Unknown | Peking Union Medical College Hospital | 100 | 2021-08-11 | 2022-05-06 |
| Application of 68Ga-Pentixafor PET/CT in Primary Aldosteronism and Pre-postoperative of SAAE 68Ga-Pentixafor - Positron-Emission Tomography | Not applicable | Recruiting | First Affiliated Hospital of Fujian Medical University | 100 | 2020-09-01 | 2026-07-21 |
| Value of Chemokine Receptor CXCR4 Imaging for Diagnosis and Prognostic Evaluation in Lymphoproliferative Diseases 68Ga-Pentixafor - Lymphoma, Multiple Myeloma | Early Phase 1 | Recruiting | First Affiliated Hospital of Fujian Medical University | 50 | 2020-08-07 | 2026-07-21 |
| Chemokine Receptor CXCR4-targeting Molecular Imaging for Metabolic Characterization of Multiple Myeloma and Lymphoma 68Ga-Pentixafor - Multiple Myeloma, Lymphoma | Early Phase 1 | Unknown | Peking Union Medical College Hospital | 100 | 2019-06-01 | 2019-12-27 |
| Gallium 68 Pentixafor in Patients With Neuroendocrine Tumors [68Ga]Pentixafor - Neuroendocrine Tumors | Early Phase 1 | Active not recruiting | Yusuf Menda | 30 | 2017-11-03 | 2025-07-14 |
Multiple Myeloma (4) · Lymphoma (2) · Erdheim-Chester Disease (1) · Hematologic Neoplasms (1) · Histiocytosis, Sinus (1) · Leukemia (1) · Lymphoma, Non-Hodgkin (1) · Neuroendocrine Tumors (1) · Thymoma (1)
Peking Union Medical College Hospital (4) · First Affiliated Hospital of Fujian Medical University (2) · Memorial Sloan Kettering Cancer Center (1) · Pentixapharm AG (1) · Yusuf Menda (1) · Zhongnan Hospital (1)
China (7) · United States (2) · Denmark (1) · France (1)
Anton Nosov, MD (1) · Fang Li, M.D. (1) · Liangdi Xie, MD (1) · M. Sue O'Dorisio, MD, PhD (1) · Qiao Yang, MD. (1) · Weibing Miao, M.D. (1) · Yong He, MD, PhD (1) · Yusuf Menda, MD (1) · Zhaohui Zhu (1)
PMID 40540129, PMID 31776631, PMID 34651291, PMID 37601238, PMID 39887860, PMID 41760826
P50CA174521 (1)